Search

Stannsoporfin

Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing

ETC-1001

ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.

TBX-3400

TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.

ATL-104

In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents.

D-Proline

D-proline is an isomer of the naturally occurring amino acid, L-Proline. D-amino acids have been found in relatively high abundance in human plasma and saliva [A19262].

Butyrfentanyl

[A182054] It is an analog of [fentanyl] with roughly 1/30 the potency.[L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic. … [L7811] This compound is a schedule I controlled substance in the USA because it is a positional isomer of 3-Methylfentanyl.

Namilumab

Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.

Lestaurtinib

PB127

R1204

R1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.